Insmed Q3 ARIKAYCE revenue $79.1M (+17% YoY); net loss $158.9M; FY23 guidance reaffirmed

INSMED Inc

2023-Q3 EPS reported -$4.06 revenue$221,515,000

ARIKAYCE global sales $79.1M for Q3, highest quarter since launch; U.S. $59.2M, Japan $16.0M.
Net loss $158.9M ($1.11/share) vs $131.1M ($1.09/share) in Q3 2022; R&D spend $109.1M.
Cash & marketable securities $786M as of Sep 30, 2023, down from $918M at June 30, 2023.
FY2023 ARIKAYCE revenue guidance reiterated at $295M-$305M; ASPEN topline data expected Q2 2024.
ARISE trial met primary endpoint; plans to explore accelerated filing for MAC lung disease label expansion.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

INSMED Inc reported the third quarter ended September 30, 2023 results: revenue $79.1 million. Guidance reaffirmed.

Period: the third quarter ended September 30, 2023
Revenue: $79.1 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Total revenue for the third quarter ended September 30, 2023 was $79.1 million

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

INSMED Inc filing history →

Source: SEC EDGAR

accession 0001140361-23-049591

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.